Viral Warts Treatment Market Share

North America Market Insights

North America is the dominant region in the market and is expected to have a market share of 40.8% by the end of 2035. The market is driven by high awareness, significant economic costs, and advanced dermatologic infrastructure. The NIH article published in March 2024 revealed that the annual direct medical costs for treating HPV-related anogenital warts and recurrent respiratory papillomatosis are USD 104 million. It also stated that anogenital warts account for approximately USD 46 million, while adult-onset RRP contributes around USD 56 million.

The U.S. viral warts treatment market is augmenting its leadership in the regional landscape owing to the increased HPV vaccination rates, which are expected to reduce the prevalence of HPV-related warts, impacting demand for treatment options. This can be testified from the NIH study in July 2023, which found that pediatricians receive the highest total return from vaccine cost reimbursements, which averaged about USD 5.08 per dose, whereas family physicians have a return margin of USD 0.34 per dose, thus suitable for market expansion.

Canada is showcasing a positive growth trajectory in the market on account of increasing awareness of sexually transmitted infections, rising healthcare access, and growing demand for both over-the-counter and prescription treatment options.  As of September 2025, Health Canada reports that 5% of sexually active individuals contract HPV at some point, and many types of HPV, low-risk strains can lead to genital warts, while high-risk types are linked to various cancers, including cervical, anal, penile, and throat cancers.

Gardasil9 and Trumenba - CDC and Private Sector Pricing Overview

Source: CDC

APAC Market Insights

The Asia Pacific is the fastest-growing region in the viral warts treatment market, significantly driven by a rise in HPV prevalence, expanding government reimbursement frameworks, and improved dermatological infrastructure. The region is experiencing a drastic shift from surgical and cryotherapy-based solutions to topical immunotherapies and affordable antiviral formulations. This transformation is mainly seen in countries such as India and China, as their market access is crucial. Market access is heavily reliant on government procurement, regional R&D incentives, and multi-tier reimbursement schemes.

China holds the largest share of the regional market owing to the rising awareness of skin-related conditions and an expanding urban population seeking medical and cosmetic treatment options. For instance, in June 2023, Pierre Fabre announced that it had inaugurated its China Innovation Center in Shanghai, marking a major step in the expansion of its R&D capabilities in this region. The center includes a formulation laboratory and consumer testing facilities, with an understanding of skin needs through collaboration with local institutions such as Beijing University Hospital.

India is gaining traction in the Asia Pacific’s viral warts treatment market, extremely supported by improved public health awareness, novel product introductions, and access to dermatological care. Flychem India Pvt Ltd in March 2025 reported that it has launched KOSAVA, which is a revolutionary high-purity encapsulated salicylic acid product that offers stability, superior skin penetration, making it highly effective for personal care and pharmaceutical formulations. The product is available both in liquid and powder variants and is designed to treat skin issues, hence denoting a wider market scope.

Europe Market Insights

Europe is the leading region in the viral warts treatment market, backed by increased HPV vaccination coverage, a growing elderly population susceptible to viral wart infections, and government-subsidized dermatologic care. As per the report from Research Nester, the  HPV-associated disorders treatment market, a crucial segment of which is genital warts, is projected to grow at a steady CAGR of 4.8%. This expansion highlights the increasing economic importance and sustained demand for effective treatments within the viral warts segment of the market.

Germany is one of Europe's biggest and most organized markets, facilitated by comprehensive outpatient wart treatments, such as immunotherapies, nitric oxide gels, and wart excisions. In February 2024, Avia Pharma Holding AB reported that it acquired Neubourg Skin Care GmbH, which is a dermatology company known for its foam-based footcare brand Allpresan. Hence, this acquisition enhances Avia’s dermatology portfolio, strengthening its position in the global landscape.

The U.K. is one of the most influential landscapes for the viral warts treatment market, strongly benefiting from therapeutic options such as cryotherapy, topical treatments, and immunomodulatory therapies. On the other hand, topical treatments such as salicylic acid are also extensively utilized owing to their cost-effectiveness. Furthermore, specialty clinics in the country are gaining enhanced traction since patients are seeking specialized care, thereby making them suitable for overall market growth.